Impact BioMedical, Inc. (IBO) Key Metrics
IBO valuation today
Trailing 12 months · as of October 17, 2026- Market cap
- $22.9M
- Enterprise value
- $79.6M
- P/E (TTM)
- 0.3
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- 654.2
- Price / book
- 5.3
- EV / EBITDA
- 4.7
- Dividend yield
- —
- Beta
- 2.73
IBO key metrics, 2017–2025
Fiscal year ended December 31, 2025 · U.S. dollarsIBO valuation Price multiples at each fiscal year-end price.
IBO returns How much profit the business earns on the capital it uses.
IBO per-share figures Results divided by the shares outstanding at year-end.
IBO financial health Debt, liquidity and how easily interest is covered.
IBO efficiency & capital use Working capital cycle and where the cash goes.
IBO valuation history
IBO returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
IBO debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
IBO cash returned to shareholders
IBO price vs earnings per share
IBO key metrics
2017–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|
| Valuation | |||||||||
| Market capitalization | $15.9M | $60.5M | — | — | — | — | — | — | — |
| Enterprise value | $16.6M | $67.4M | — | — | — | — | — | — | — |
| Price / sales | 497.9 | 37.4 | — | — | — | — | — | — | — |
| Price / book | 1.3 | 14.2 | — | — | — | — | — | — | — |
| EV / sales | 517.2 | 41.6 | — | — | — | — | — | — | — |
| Earnings yield | −74.3% | −40.8% | — | — | — | — | — | — | — |
| Free cash flow yield | −11.9% | −9.3% | — | — | — | — | — | — | — |
| Shareholder yield (dividends + buybacks) | — | 0.0% | — | — | — | — | — | — | — |
| Share price at fiscal year-end | $6.37 | $18.30 | — | — | — | — | — | — | — |
| Per share | |||||||||
| Revenue per share | $0.01 | $0.49 | $0.22 | — | — | — | $0.00 | $0.00 | $0.00 |
| Earnings per share | −$4.74 | −$7.47 | −$0.91 | — | — | — | −$0.05 | −$0.01 | −$0.04 |
| Operating cash flow per share | −$0.76 | −$1.70 | −$0.60 | — | — | — | −$0.01 | −$0.01 | −$0.03 |
| Free cash flow per share | −$0.76 | −$1.70 | −$0.60 | — | — | — | −$0.01 | −$0.01 | −$0.03 |
| Cash per share | $0.00 | $0.60 | $0.00 | — | — | — | $0.01 | $0.02 | $0.01 |
| Book value per share | $5.04 | $1.29 | $5.28 | — | — | — | $0.01 | $0.02 | $0.03 |
| Tangible book value per share | −$1.75 | −$9.47 | −$3.94 | — | — | — | $0.01 | $0.02 | $0.03 |
| Capex per share | $0.00 | $0.00 | $0.00 | — | — | — | $0.00 | $0.00 | $0.00 |
| Debt per share | $0.25 | $2.68 | $2.53 | — | — | — | — | — | — |
| Shares outstanding | 2.5M | 3.3M | 4.8M | — | — | — | 11.8M | 9.8M | 10.2M |
| Change in shares outstanding | −24.4% | −30.7% | — | — | — | — | +20.6% | −3.9% | — |
| Returns & profitability | |||||||||
| Return on equity (ROE) | −140.4% | −167.6% | −15.8% | −21.3% | −18.9% | −3.1% | −404.2% | −39.9% | −138.3% |
| Return on invested capital (ROIC) | −27.7% | −93.8% | −8.3% | −6.1% | −6.1% | −3.6% | — | — | 20.8% |
| Return on assets (ROA) | −62.8% | −76.1% | −9.5% | −13.7% | −13.5% | −2.5% | −353.5% | −36.5% | −127.3% |
| Return on tangible assets | — | — | −700.5% | −514.7% | −69.2% | −80.8% | −506.0% | −45.2% | −127.3% |
| Free cash flow margin | — | −347.9% | −278.5% | — | — | — | — | — | — |
| Financial health | |||||||||
| Total debt | $621,000 | $8.9M | $12.1M | $10.0M | $12.5M | $1.1M | — | — | — |
| Cash & short-term investments | $3,000 | $2.0M | $1,000 | $2,000 | $46,000 | $72,347 | $97,666 | $204,929 | $51,922 |
| Net debt | $618,000 | $6.9M | $12.1M | $10.0M | $12.5M | $986,882 | −$97,666 | −$204,929 | −$51,922 |
| Debt / equity | 0.05 | 2.08 | 0.48 | 0.34 | 0.34 | 0.03 | — | — | — |
| Debt / assets | 0.04 | 0.44 | 0.27 | 0.21 | 0.22 | 0.02 | — | — | — |
| Net debt / EBITDA | — | — | — | — | — | — | −153.08 | — | −0.81 |
| Current ratio | 0.35 | 0.25 | 0.03 | 0.01 | 0.02 | 0.10 | 5.31 | 10.81 | 12.61 |
| Quick ratio | 0.30 | 0.25 | 0.03 | 0.01 | 0.02 | 0.10 | 5.31 | 10.81 | 12.61 |
| Interest coverage | -5.4 | -244.9 | -9.1 | -7.4 | -11.3 | — | — | — | — |
| Working capital | −$751,000 | −$7.3M | −$12.8M | −$10.5M | −$12.4M | −$961,418 | $93,617 | $197,115 | $295,224 |
| Invested capital | $13.2M | $11.1M | $37.3M | $39.5M | $49.1M | $38.9M | −$2,775 | −$7,814 | $243,302 |
| Tangible asset value | −$1.4M | −$28.4M | −$15.8M | −$12.5M | −$6.3M | −$5.6M | $94,891 | $197,115 | $295,224 |
| Net current asset value | −$1.4M | −$10.6M | −$16.0M | −$13.7M | −$16.2M | −$6.2M | $93,617 | $197,115 | $295,224 |
| Graham net-net per share | −$0.67 | −$3.30 | −$3.38 | — | — | — | $0.01 | $0.02 | $0.00 |
| Capital allocation | |||||||||
| Dividends paid | — | — | — | $410,000 | $410,000 | — | — | — | — |
| Share buybacks (net) | — | $0 | — | $46,450 | $46,450 | — | — | — | — |
| Capex / revenue | 0.0% | 0.0% | 1.7% | 552.0% | 552.0% | — | — | — | — |
| Capex / depreciation | 0.00 | 0.00 | 0.02 | 0.25 | 0.25 | 0.00 | 6.00 | 0.00 | 0.00 |
| Stock-based compensation / revenue | 40.6% | 1.2% | 0.0% | 1,807.1% | — | — | — | — | — |
| R&D / revenue | 1,062.5% | 17.2% | 163.6% | 2,452.0% | 2,452.0% | — | — | — | — |
| SG&A / revenue | 6,175.0% | 112.9% | 107.2% | 2,744.0% | 2,744.0% | — | — | — | — |
| Efficiency | |||||||||
| Days sales outstanding | 2,207.1 | 58.0 | 61.5 | 777.5 | 770.4 | — | — | — | — |
| Days of inventory on hand | 27.0 | -0.1 | — | — | — | — | — | — | — |
| Days payables outstanding | 284.5 | 186.9 | 223.4 | 107.2 | 20.4 | — | — | — | — |
| Cash conversion cycle (days) | 1,949.6 | -129.0 | -161.9 | 670.2 | 750.0 | — | — | — | — |
| Receivables turnover | 0.17 | 6.29 | 5.94 | 0.47 | 0.47 | 0.00 | 0.00 | 0.00 | 0.00 |
| Payables turnover | 1.28 | 1.95 | 1.63 | 3.40 | 17.91 | — | — | — | — |
| Inventory turnover | 13.52 | — | — | — | — | — | — | — | — |
| Asset turnover | 0.00 | 0.05 | 0.02 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average receivables | $193,500 | $257,500 | $173,500 | $106,500 | $105,532 | $24,627 | $19,784 | $16,498 | $28,619 |
| Average payables | $330,500 | $573,000 | $685,500 | $327,000 | $62,134 | $9,267 | — | — | — |
| Average inventory | $31,368 | −$265 | — | — | — | — | — | — | — |
| Intangibles / total assets | 97.6% | 175.4% | 98.6% | 97.1% | 81.9% | 98.5% | 0.0% | 0.0% | 0.0% |
Computed from IBO's annual financial statements (latest annual report filed March 11, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
IBO valuation and financial ratios
Based on the latest twelve months, the trailing P/E is 0.3. Impact BioMedical earned a return on equity of −140.4% and a return on invested capital of −27.7% in fiscal 2025. It ended the year with $0.6 million of debt and $0.0 million in cash and short-term investments, net debt of $0.6 million. The share count fell 75.5% from 10.2M to 2.5M over 8 years.
See the IBO income statement, the IBO chart for price history, or the IBO stock overview for the latest quote and news.
IBO key metrics FAQ
What is Impact BioMedical's P/E ratio?
Impact BioMedical's trailing P/E ratio is 0.3 based on the last twelve months of earnings (as of October 17, 2026). At the end of fiscal 2025 it was —.
What is Impact BioMedical's return on equity?
Impact BioMedical's return on equity (ROE) was −140.4% in fiscal 2025: net income of -$11.8 million on average shareholders' equity of $8.4 million.
What is Impact BioMedical's ROIC?
Impact BioMedical's return on invested capital was −27.7% in fiscal 2025, using after-tax operating income divided by average debt plus equity minus cash.
How much debt does Impact BioMedical have?
Impact BioMedical had total debt of $0.6 million at the end of fiscal 2025, a debt-to-equity ratio of 0.05.
What is Impact BioMedical's free cash flow yield?
Impact BioMedical generated -$1.9 million of free cash flow in fiscal 2025, a free cash flow yield of −11.9% on its market value at year-end ($15.9 million).
What is Impact BioMedical's current ratio?
Impact BioMedical's current ratio was 0.35 at the end of fiscal 2025: current assets were 0.35 times current liabilities.